AAPL342.93-1.24 (-0.36%) ▼|ABBV290.03+1.79 (+0.62%) ▲|ABT110.78-2.82 (-2.48%) ▼|ACN258.00-7.17 (-2.70%) ▼|ADBE240.87-5.57 (-2.26%) ▼|AMAT330.01+10.76 (+3.37%) ▲|AMD438.74+34.34 (+8.49%) ▲|AMGN461.36+1.08 (+0.23%) ▲|AMT193.06-0.93 (-0.48%) ▼|AMZN261.81+1.60 (+0.61%) ▲|AVGO290.79-0.75 (-0.26%) ▼|AXP321.71-3.26 (-1.00%) ▼|BA173.18+0.68 (+0.39%) ▲|BAC49.97+0.21 (+0.41%) ▲|BKNG164.37-4.35 (-2.58%) ▼|BLK1,183.43+12.76 (+1.09%) ▲|BMY62.88-0.25 (-0.40%) ▼|BNY148.47+0.98 (+0.66%) ▲|BRK-B573.20+0.87 (+0.15%) ▲|C119.98+1.53 (+1.29%) ▲|CAT556.69+3.05 (+0.55%) ▲|CL97.08-1.61 (-1.63%) ▼|CMCSA24.61-0.34 (-1.36%) ▼|COF201.52-2.33 (-1.14%) ▼|COP136.82+1.36 (+1.00%) ▲|COST1,061.45-4.15 (-0.39%) ▼|CRM215.13-7.28 (-3.27%) ▼|CSCO93.51-2.21 (-2.30%) ▼|CVS83.60+2.27 (+2.79%) ▲|CVX213.88+0.95 (+0.45%) ▲|DE673.69+10.38 (+1.56%) ▲|DHR229.76+3.42 (+1.51%) ▲|DIS117.22+0.00 (+0.00%) ▲|DUK128.65-1.43 (-1.10%) ▼|EMR161.75-0.87 (-0.53%) ▼|FDX308.12-8.69 (-2.74%) ▼|GD355.04-1.31 (-0.37%) ▼|GE322.41+7.68 (+2.44%) ▲|GEV759.68-10.83 (-1.41%) ▼|GILD168.07+0.50 (+0.30%) ▲|GM87.41-1.92 (-2.15%) ▼|GOOG284.24+2.50 (+0.89%) ▲|GOOGL285.31+2.74 (+0.97%) ▲|GS874.10+5.15 (+0.59%) ▲|HD344.50-5.45 (-1.56%) ▼|HON220.00+4.22 (+1.96%) ▲|IBM244.28-2.83 (-1.15%) ▼|INTC55.93+3.68 (+7.04%) ▲|INTU341.10-13.74 (-3.87%) ▼|ISRG454.33-14.20 (-3.03%) ▼|JNJ275.26+2.94 (+1.08%) ▲|JPM336.59-0.75 (-0.22%) ▼|KO96.27+0.54 (+0.56%) ▲|LIN518.36-2.87 (-0.55%) ▼|LLY1,368.38+3.65 (+0.27%) ▲|LMT571.98-4.18 (-0.73%) ▼|LOW225.22-2.02 (-0.89%) ▼|LRCX198.72+13.52 (+7.30%) ▲|MA657.52+1.60 (+0.24%) ▲|MCD277.65-0.39 (-0.14%) ▼|MDLZ66.50-0.32 (-0.48%) ▼|MDT102.58-2.26 (-2.16%) ▼|META617.42+12.34 (+2.04%) ▲|MMM187.05-0.72 (-0.38%) ▼|MO76.59-0.99 (-1.28%) ▼|MRK147.10+0.16 (+0.11%) ▲|MS183.12+0.68 (+0.37%) ▲|MSFT532.75-3.18 (-0.59%) ▼|MU682.73+26.34 (+4.01%) ▲|NEE87.54-0.72 (-0.81%) ▼|NFLX63.76-1.81 (-2.75%) ▼|NKE38.62-0.94 (-2.38%) ▼|NOW102.10-0.26 (-0.25%) ▼|NVDA185.84+4.24 (+2.34%) ▲|ORCL113.65-1.52 (-1.32%) ▼|PEP141.61-1.10 (-0.77%) ▼|PFE29.30-0.16 (-0.53%) ▼|PG166.01-1.09 (-0.65%) ▼|PLTR160.16+5.17 (+3.34%) ▲|PM199.55-1.96 (-0.97%) ▼|QCOM164.01+7.26 (+4.63%) ▲|RTX192.59+0.71 (+0.37%) ▲|SBUX105.79-0.37 (-0.35%) ▼|SCHW91.56-1.02 (-1.10%) ▼|SO92.48-0.87 (-0.93%) ▼|SPG228.46+1.91 (+0.84%) ▲|T21.70-0.12 (-0.55%) ▼|TMO696.33+19.39 (+2.86%) ▲|TMUS160.37-0.23 (-0.14%) ▼|TSLA358.50+14.81 (+4.31%) ▲|TXN275.91-2.24 (-0.81%) ▼|UBER69.02+0.24 (+0.35%) ▲|UNH394.96-0.77 (-0.19%) ▼|UNP291.92-6.04 (-2.03%) ▼|UPS108.31-2.73 (-2.46%) ▼|USB59.40-0.36 (-0.59%) ▼|V423.28+0.69 (+0.16%) ▲|VZ45.87-0.26 (-0.55%) ▼|WFC84.12-0.18 (-0.21%) ▼|WMT126.24-1.48 (-1.16%) ▼|XOM166.12+0.82 (+0.50%) ▲|AAPL342.93-1.24 (-0.36%) ▼|ABBV290.03+1.79 (+0.62%) ▲|ABT110.78-2.82 (-2.48%) ▼|ACN258.00-7.17 (-2.70%) ▼|ADBE240.87-5.57 (-2.26%) ▼|AMAT330.01+10.76 (+3.37%) ▲|AMD438.74+34.34 (+8.49%) ▲|AMGN461.36+1.08 (+0.23%) ▲|AMT193.06-0.93 (-0.48%) ▼|AMZN261.81+1.60 (+0.61%) ▲|AVGO290.79-0.75 (-0.26%) ▼|AXP321.71-3.26 (-1.00%) ▼|BA173.18+0.68 (+0.39%) ▲|BAC49.97+0.21 (+0.41%) ▲|BKNG164.37-4.35 (-2.58%) ▼|BLK1,183.43+12.76 (+1.09%) ▲|BMY62.88-0.25 (-0.40%) ▼|BNY148.47+0.98 (+0.66%) ▲|BRK-B573.20+0.87 (+0.15%) ▲|C119.98+1.53 (+1.29%) ▲|CAT556.69+3.05 (+0.55%) ▲|CL97.08-1.61 (-1.63%) ▼|CMCSA24.61-0.34 (-1.36%) ▼|COF201.52-2.33 (-1.14%) ▼|COP136.82+1.36 (+1.00%) ▲|COST1,061.45-4.15 (-0.39%) ▼|CRM215.13-7.28 (-3.27%) ▼|CSCO93.51-2.21 (-2.30%) ▼|CVS83.60+2.27 (+2.79%) ▲|CVX213.88+0.95 (+0.45%) ▲|DE673.69+10.38 (+1.56%) ▲|DHR229.76+3.42 (+1.51%) ▲|DIS117.22+0.00 (+0.00%) ▲|DUK128.65-1.43 (-1.10%) ▼|EMR161.75-0.87 (-0.53%) ▼|FDX308.12-8.69 (-2.74%) ▼|GD355.04-1.31 (-0.37%) ▼|GE322.41+7.68 (+2.44%) ▲|GEV759.68-10.83 (-1.41%) ▼|GILD168.07+0.50 (+0.30%) ▲|GM87.41-1.92 (-2.15%) ▼|GOOG284.24+2.50 (+0.89%) ▲|GOOGL285.31+2.74 (+0.97%) ▲|GS874.10+5.15 (+0.59%) ▲|HD344.50-5.45 (-1.56%) ▼|HON220.00+4.22 (+1.96%) ▲|IBM244.28-2.83 (-1.15%) ▼|INTC55.93+3.68 (+7.04%) ▲|INTU341.10-13.74 (-3.87%) ▼|ISRG454.33-14.20 (-3.03%) ▼|JNJ275.26+2.94 (+1.08%) ▲|JPM336.59-0.75 (-0.22%) ▼|KO96.27+0.54 (+0.56%) ▲|LIN518.36-2.87 (-0.55%) ▼|LLY1,368.38+3.65 (+0.27%) ▲|LMT571.98-4.18 (-0.73%) ▼|LOW225.22-2.02 (-0.89%) ▼|LRCX198.72+13.52 (+7.30%) ▲|MA657.52+1.60 (+0.24%) ▲|MCD277.65-0.39 (-0.14%) ▼|MDLZ66.50-0.32 (-0.48%) ▼|MDT102.58-2.26 (-2.16%) ▼|META617.42+12.34 (+2.04%) ▲|MMM187.05-0.72 (-0.38%) ▼|MO76.59-0.99 (-1.28%) ▼|MRK147.10+0.16 (+0.11%) ▲|MS183.12+0.68 (+0.37%) ▲|MSFT532.75-3.18 (-0.59%) ▼|MU682.73+26.34 (+4.01%) ▲|NEE87.54-0.72 (-0.81%) ▼|NFLX63.76-1.81 (-2.75%) ▼|NKE38.62-0.94 (-2.38%) ▼|NOW102.10-0.26 (-0.25%) ▼|NVDA185.84+4.24 (+2.34%) ▲|ORCL113.65-1.52 (-1.32%) ▼|PEP141.61-1.10 (-0.77%) ▼|PFE29.30-0.16 (-0.53%) ▼|PG166.01-1.09 (-0.65%) ▼|PLTR160.16+5.17 (+3.34%) ▲|PM199.55-1.96 (-0.97%) ▼|QCOM164.01+7.26 (+4.63%) ▲|RTX192.59+0.71 (+0.37%) ▲|SBUX105.79-0.37 (-0.35%) ▼|SCHW91.56-1.02 (-1.10%) ▼|SO92.48-0.87 (-0.93%) ▼|SPG228.46+1.91 (+0.84%) ▲|T21.70-0.12 (-0.55%) ▼|TMO696.33+19.39 (+2.86%) ▲|TMUS160.37-0.23 (-0.14%) ▼|TSLA358.50+14.81 (+4.31%) ▲|TXN275.91-2.24 (-0.81%) ▼|UBER69.02+0.24 (+0.35%) ▲|UNH394.96-0.77 (-0.19%) ▼|UNP291.92-6.04 (-2.03%) ▼|UPS108.31-2.73 (-2.46%) ▼|USB59.40-0.36 (-0.59%) ▼|V423.28+0.69 (+0.16%) ▲|VZ45.87-0.26 (-0.55%) ▼|WFC84.12-0.18 (-0.21%) ▼|WMT126.24-1.48 (-1.16%) ▼|XOM166.12+0.82 (+0.50%) ▲|
18.5 C
New York
Friday, November 6, 2026

Tag: future

Tax Freedom Day is tomorrow–June 9–when Canadians finally start working for themselves

VANCOUVER, BC, June 8, 2026 /CNW/ - Tomorrow, June 9, Canadians will celebrate Tax Freedom Day, the day in the year when they start working...

Godrej Industries Group Celebrates Pride@Godrej 2026

~ Godrej DEI Lab Launches Queer India Now!, a new anthology Under Queer Directions ~~ Introduces 'Queer India Fellowship' to Nurture Emerging Queer Leaders...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

LG Teams with NVIDIA to Shape the Future with M.A.P. (Mobility / AI Infra / Physical AI)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- LG and NVIDIA are expanding their strategic collaboration across industries, Physical AI, AI Infra and mobility...

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

Solidion Technology Granted 7 New Patents on Composite Anode Materials For Batteries Targeting Humanoid Robots, Space-Based Artificial Intelligence Data Centers and the Lunar Economy

 The newly granted patents further strengthen an already globally leading portfolio of patents on anode materials for high-energy and fast-charging lithium batteriesDALLAS, June 8,...

Millions of students are finishing school this summer. Many still don’t know what’s next.

A Gap Year or Academic Year abroad is far more than a year off, it's an opportunity for young people to gain life experience and improve language skills.

Telenor receives approval to acquire GlobalConnect’s consumer business in Norway

The Norwegian Competition Authority has approved Telenor's acquisition of GlobalConnect's Norwegian fibre business for residential customers

Virbac: modalités de mise à disposition ou de consultation des documents préparatoires à l’assemblée générale mixte du 29 juin 2026

Les actionnaires de la société VIRBAC sont invités à participer à l’assemblée générale mixte qui se tiendra le lundi 29 juin 2026 à 14 heures, dans les bâtiments de VIRBAC direction, 13ème rue LID 06517 Carros. 

NBPE Announces Transaction in Own Shares

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Casino Group Communication

Casino Group and the Zouari Family strengthen their historic partnership to accelerate in convenience retail

New Linux Foundation Report Finds AI is Driving Positive Tech Hiring Trends in Europe Amid Growing Security and Skills Gaps

Increased AI deployment results in an aggregated net hiring effect of +27% expected in 2026, while upskilling internal talent emerges as the primary strategy...

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFuture